XtalPi Advances Global STEM Education Through AI-Powered Science Outreach

Blog details
3 min read
Share this:

As a global innovator at the forefront of AI-driven drug discovery, XtalPi (HKEX: 2228.HK) extends its technological leadership into social responsibility. Through cross-border science education initiatives, the company is inspiring next-generation scientists worldwide while demonstrating how cutting-edge technologies address humanity’s pressing challenges.

Flagship Program: AI Drug Discovery Workshops
At Shanghai Exhibition Center, XTALPI’s Future Scientist Series captivated young learners with interactive sessions:

  • Decoding Medicine: Interactive analysis of drug labels
  • Molecular Modeling: Hands-on construction of 3D drug structures
  • AI in Action: Case studies on machine learning applications in pharmaceutical R&D

Led by Head of Brand & Culture, the program blended multimedia learning with tangible experimentation. Its success garnered coverage from Shanghai-based Wen Wei Bao and created family learning moments bridging scientific theory with real-world impact.

Driving Scientific Literacy Through Global Engagement
Leveraging its multidisciplinary expertise, world-class scientific talent, and globally distributed lab networks, XTALPI has conducted cross-border science outreach programs reaching:
• Students & educators from 7+ regions: Shenzhen, Shanghai, Hong Kong, U.S., Abu Dhabi (UAE), Africa, and the Caribbean

CAS Youth Science Camp (Chinese Academy of Sciences collaboration)

Shanghai: Zhangjiang AI Innovation Expo 2024

Community Science Workshops for local families

International School Leadership Forum

Corporate Citizenship Vision
“True innovation must serve humanity,” said XTALPI leadership. “Through quantum physics-based AI and robotic platforms, we’re not just accelerating drug discovery – we’re cultivating global scientific literacy to build a healthier, more sustainable future.”

Your next success starts here

Recommended articles

XtalPi and Baicheng Medicine Announce Strategic Collaboration to Advance Innovative Drug Development
XtalPi Leadership Visits China Merchants Group to Explore Strategic Collaboration in AI-Driven Innovation
XtalPi Announces Milestone Achievement in Collaboration with PharmaEngine on Next-Generation PRMT5 Inhibitor PEP08
Signet Therapeutics, Incubated by XtalPi, Nominated for 2025 Prix Galien USA Best Biotechnology Award for First-in-Class Diffuse Gastric Cancer Drug SIGX1094R

XtalPi Newsletter